Why Did Centessa's Shares Plunge 10% Today?

Loading...
Loading...
  • Centessa Pharmaceuticals plc CNTA announced proof-of-mechanism data from the first three subjects in Phase 1 Part B study of ZF874 in Alpha-1 Antitrypsin Deficiency (AATD). 
  • AATD is an autosomal recessive disorder frequently caused by missense mutations in the A1AT gene. 
  • Individuals with AATD regularly suffer from chronic obstructive pulmonary disease and/or liver disease.
  • In both PiMZ subjects dosed with 15 mg/kg BID of ZF874, the observed increase in functional A1AT was between 3.5 and 6 micromolar. 
  • Consistent with a pharmacological effect for ZF874, A1AT levels returned to baseline by 28 days after dosing.
  • Pharmacokinetic analysis showed a two-fold higher exposure to ZF874 in one subject. 
  • CNTA shares are plunging as investors react when this one subject did show a two-fold increase in functional A1AT but also experienced severe liver toxicity, with a delayed, reversible increase in ALT and AST (enzymes suggesting liver damage). 
  • All other liver function tests remained in the normal range. 
  • Read Next: Centessa Stock Surges On Positive Data From Hemophilia Candidate.
  • Price Action: CNTA shares are down 18.55% at $14.01 on Monday.
Posted In: BiotechNewsShort IdeasHealth CareSmall CapMoversTrading IdeasGeneralBriefswhy it's moving
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...